The estimated Net Worth of Steven K Rogers is at least $1.48 Milión dollars as of 22 November 2004. Steven Rogers owns over 20,000 units of Icad Inc stock worth over $1,335,448 and over the last 21 years Steven sold ICAD stock worth over $143,800.
Steven has made over 2 trades of the Icad Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Steven sold 20,000 units of ICAD stock worth $79,000 on 22 November 2004.
The largest trade Steven's ever made was selling 20,000 units of Icad Inc stock on 22 November 2004 worth over $79,000. On average, Steven trades about 13,333 units every 32 days since 2004. As of 22 November 2004 Steven still owns at least 960,754 units of Icad Inc stock.
You can see the complete history of Steven Rogers stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is C/O ICAD, INC., 4 TOWNSEND WEST, SUITE 17, NASHUA, NH, 03063.
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton a Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Icad Inc executives and other stock owners filed with the SEC include: